CanSino Biologics Inc
06185
Company Profile
Business description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,105
Stocks News & Analysis
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,657.50 | 2.20 | 0.03% |
| CAC 40 | 7,747.35 | 45.40 | 0.59% |
| DAX 40 | 22,428.57 | 127.82 | 0.57% |
| Dow JONES (US) | 45,166.64 | 793.47 | -1.73% |
| FTSE 100 | 10,079.79 | 112.44 | 1.13% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 51,885.85 | 1,487.22 | -2.79% |
| NZX 50 Index | 12,748.92 | 186.47 | -1.44% |
| S&P 500 | 6,368.85 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,461.00 | 0.10 | 0.00% |
| SSE Composite Index | 3,923.29 | 9.56 | 0.24% |